Skip to main content

Chronic Progressive External Ophthalmoplegia (CPEO)

A mitochondrial disorder causing slowly progressive weakness of the eye muscles, leading to droopy eyelids and limited eye movement.

Chronic progressive external ophthalmoplegia (CPEO) is a condition characterized by slowly progressive weakness of the muscles that move the eyes and eyelids. It's usually caused by mitochondrial dysfunction—problems with the energy-producing parts of cells. The condition develops gradually and is often associated with other systemic problems.

Key Takeaways

  • Progressive droopy eyelids (ptosis) and limited eye movement
  • Usually caused by mitochondrial disease
  • Develops slowly over years to decades
  • Often little or no double vision because both eyes affected equally
  • May be associated with other body systems involvement

Understanding CPEO

The muscles that move the eyes and lift the eyelids require significant energy. In CPEO, mitochondrial dysfunction impairs energy production in these muscles, causing them to weaken progressively. Because the condition develops slowly and affects both eyes similarly, the brain adapts, and double vision is often absent or minimal.

Symptoms

Eye and Eyelid Symptoms

Ptosis (droopy eyelids)

  • Usually the first symptom
  • Bilateral (both eyelids)
  • Progressive—worsens over years
  • May lift chin to see under lids

Limited eye movement

  • Gradual restriction of gaze in all directions
  • Usually symmetric
  • May not cause double vision

Absence of Double Vision

  • Symmetry means eyes remain aligned
  • Brain adapts to gradual changes
  • If diplopia present, consider other diagnoses

Associated Conditions (CPEO "Plus")

CPEO may occur with other features:

Kearns-Sayre Syndrome:

  • Heart conduction abnormalities (dangerous)
  • Retinal pigmentary changes
  • Onset before age 20

Other associations:

  • Hearing loss
  • Muscle weakness
  • Ataxia (balance problems)
  • Endocrine problems (diabetes, hypoparathyroidism)
  • Short stature

Causes

Mitochondrial DNA Mutations

  • Most common cause
  • Large deletions in mitochondrial DNA
  • Point mutations

Nuclear DNA Mutations

  • Genes affecting mitochondrial function
  • May have autosomal dominant or recessive inheritance

Sporadic

  • Many cases have no family history
  • New mutations

Diagnosis

Clinical Features

  • Progressive bilateral ptosis
  • Symmetric ophthalmoplegia
  • Slow progression
  • Often no diplopia

Genetic Testing

  • Mitochondrial DNA analysis
  • Nuclear gene testing
  • Blood or muscle sample

Muscle Biopsy

  • Ragged red fibers (classic finding)
  • Cytochrome oxidase-negative fibers
  • May confirm mitochondrial myopathy

Other Testing

  • ECG/cardiac monitoring (essential—look for heart block)
  • Audiometry (hearing)
  • Retinal examination
  • Blood tests (glucose, lactate, hormones)

Rule Out Myasthenia Gravis

Myasthenia gravis can mimic CPEO but is treatable. Testing (acetylcholine receptor antibodies, single-fiber EMG) should be done.

Treatment

No Cure

Currently, no treatment reverses or stops CPEO progression.

Supportive Management

For ptosis:

  • Ptosis crutches on glasses
  • Surgical lid elevation (frontalis sling)
  • Tape or props

For limited eye movement:

  • Usually not needed if no diplopia
  • Head positioning to use available movement

Monitor for Systemic Problems

  • Regular cardiac monitoring (ECG, Holter)
  • Pacemaker if heart block develops
  • Hearing assessment
  • Endocrine screening

Supplements (Uncertain Benefit)

  • Coenzyme Q10
  • L-carnitine
  • B vitamins
  • Evidence limited, but often tried

Living with CPEO

Practical Adaptations

  • Tilt head back to see under droopy lids
  • Consider driving implications
  • Adequate lighting
  • Safety considerations if balance affected

Cardiac Precautions

  • Regular ECG monitoring essential
  • Pacemaker if needed
  • Avoid certain medications if heart block present

Genetic Counseling

  • Inheritance patterns vary
  • Some cases sporadic
  • Important for family planning

Prognosis

Variable

  • Slowly progressive over decades
  • Life expectancy depends on associated features
  • Kearns-Sayre syndrome has more serious cardiac implications
  • Isolated CPEO often compatible with near-normal lifespan

Quality of Life

  • Functional vision usually maintained
  • Ptosis surgery can improve appearance and function
  • Adaptation to limitations

Frequently Asked Questions

Why don't I have double vision if my eye muscles are weak?

Because CPEO affects both eyes equally and progresses slowly, your eyes remain aligned even though they don't move well. Your brain adapts to the gradual changes. This is different from conditions like third nerve palsy, where one eye is suddenly affected.

Is this the same as myasthenia gravis?

No, though they can look similar. Myasthenia gravis is an autoimmune condition that's treatable, while CPEO is a mitochondrial disorder without specific treatment. Testing can distinguish them—this is important because myasthenia can be effectively managed.

Will I go blind?

No. CPEO affects the muscles that move the eyes and eyelids, not vision itself. Your eyelids may droop so much that they block your vision, but surgery can correct this. Some patients with CPEO "plus" syndromes may have retinal changes affecting vision, but this is separate from the muscle weakness.

Do I need a pacemaker?

Not everyone with CPEO needs a pacemaker, but heart conduction problems are a serious concern, especially in Kearns-Sayre syndrome. Regular ECG monitoring is essential, and a pacemaker is recommended if significant heart block develops.

References

Medically Reviewed Content

This article meets our editorial standards

Written by:
Hashemi Eye Care Medical Team
Medically reviewed by:
Board-Certified Neuro-Ophthalmologist (MD, Neuro-Ophthalmology)
Last reviewed:
January 30, 2025